title: Rituximab in primary conjunctiva lymphoma.
abstract: Our experience with a patient with a primary conjunctiva lymphoma who was treated with conventional dose of rituximab obtaining a complete response without acute and late local toxicity for the eye.
authors.affiliation: Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Bologna, Italy. plzinzo@med.unibo.it
authors.forename: Pier Luigi
authors.initials: PL
authors.lastname: Zinzani
authors.forename: Lapo
authors.initials: L
authors.lastname: Alinari
authors.forename: Vittorio
authors.initials: V
authors.lastname: Stefoni
authors.forename: Antonio
authors.initials: A
authors.lastname: Loffredo
authors.forename: Patrizia
authors.initials: P
authors.lastname: Pichierri
authors.forename: Ennio
authors.initials: E
authors.lastname: Polito
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003230:Conjunctival Neoplasms / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D000970:Antineoplastic Agents; D000069283:Rituximab